Ipratropium Steri-Neb Teva (Ipratropium Bromide)

Ipratropium bromide is a bronchodilator that acts on the airways to relieve obstruction in chronic respiratory diseases.

• Chronic obstructive pulmonary disease (COPD): improves airflow, reduces dyspnea and lowers the frequency of exacerbations.
• Asthma: provides additional bronchodilation when combined with other controller medications, helping to control symptoms and prevent bronchospasm.
• Chronic bronchitis: decreases mucus secretion and eases cough by relaxing airway smooth muscle.

• Ipratropium bromide selectively blocks muscarinic M3 receptors on airway smooth muscle and submucosal glands. By competitively inhibiting acetylcholine‑mediated contraction, it reduces bronchoconstriction and mucus production, producing bronchodilation. The antagonism is reversible, allowing normal cholinergic activity to resume after clearance, with onset within minutes and effects lasting several hours, supporting maintenance therapy.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dry mouth: sensation of reduced saliva production.
• Cough or throat irritation: irritation from inhaled solution.
• Headache: mild to moderate intensity.
• Dizziness: transient light‑headedness.
• Nausea: occasional upset stomach.
• Nasal congestion: mild blockage of nasal passages.

Serious or Rare Side Effects

• Paradoxical bronchospasm: sudden worsening of breathing difficulty.
• Angioedema or severe allergic reaction: swelling of face, lips, or throat.
• Urinary retention: difficulty emptying the bladder, especially in predisposed patients.
• Increased intra‑ocular pressure: risk for patients with glaucoma.

When prescribing Ipratropium bromide, clinicians should consider several safety measures.

• Assess renal function: dose may need adjustment in severe renal impairment.
• Avoid use in patients with narrow‑angle glaucoma: anticholinergic effect can raise intra‑ocular pressure.
• Use cautiously in patients with urinary retention: may exacerbate symptoms.
• Monitor for paradoxical bronchospasm: discontinue if severe breathing difficulty occurs.
• Do not combine with other anticholinergic inhalers unless directed: risk of additive anticholinergic load.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Ipratropium bromide can interact with other medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Concurrent use with other muscarinic antagonists (e.g., tiotropium): may cause excessive anticholinergic effects.
• Combination with drugs that prolong QT interval: increased risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• Beta‑2 agonists: additive bronchodilation may increase heart rate.
• Theophylline: possible increase in theophylline plasma levels.
• Antihistamines: combined anticholinergic activity may enhance dry mouth and urinary retention.